Global Gout Therapeutics Market Overview
Gout is a type of inflammatory arthritis which develops in some individuals who have high levels of uric acid in their blood. The accumulation of acid causes needle like crystal formation in the joints and can cause sudden pain, redness, tenderness, warmth and swelling. There are several types of gout which includes asymptomatic hyperuricemia, acute gout, interval gout and chronic gout. The symptoms of gout includes lingering discomfort, inflammation and redness, limited range of motion, intense joint pain.
The accumulation of urate crystals in the joints results in severe inflammation and pain. High uric acid in the blood stream is the main cause of gout. Foods such as meats and seafood promotes higher levels of uric acid. Uric acid in the bloodstream passes through the pair of kidneys which gets eliminated. There are times during which the body produces too much uric acid, whereas, the kidney excretes too little uric acid. This causes the accumulation of uric acid in the blood which results in gout. Gout can also cause severe health complications which includes kidney stones and recurrent gout that can further cause gradual damage to the neighboring tissues and joints. If the crystals get accumulated in the urinary tract, it can cause kidney stones. Proper management of gout includes therapy duration, comorbidities, adjunctive measures, gout flare prophylaxis and many more.
Market Size and Forecast
The market is observing vibrant growth on account of increasing number of geriatric population coupled with rising alcohol consumption among people. Rising levels of uric acid in the body and several metabolic disorders are expected to drive the growth of the market. Rising adoption of combination therapies and growing potential of biologics are also the factors which are supporting the growth of the market. The increasing popularity of OTC (over-the-counter) drugs which includes corticosteroids, oral colchicine and NASAIDs are also expected to support the market growth. Further, proper reimbursement policies are also anticipated to augment the growth of the market over the forecast period i.e. 2019-2027.
The gout therapeutics market is anticipated to record a CAGR of 15.7% over the forecast period. The market is segmented by drug class into corticosteroids, colchicine, urate-lowering agents & NSAIDs, out of which, the non-steroidal anti-inflammatory drugs (NSAIDs) are anticipated to dominate the market on account of low cost, easy availability and superior level of penetration of drug. Additionally, colchicines are also expected to have a significant market share in the overall market on account of higher effectiveness to reduce severe inflammatory response.
Get more information on this report: Download Sample PDF
Growth Drivers
Rising Geriatric Population
The geriatric population are more susceptible and sensitive to gout.Gout in the middle aged population is totally different from gout in the geriatric population. According to the statistics by the World Bank, the total geriatric population was 8.482 percent of the total worldwide population in the year 2016 which enhanced to 8.696 percent of the total population during the year 2017. The older people are more prone to gout because of the rapid accumulation of uric acid in the blood. The effectiveness of functioning of kidneys in the older people gradually decreases as a result of which the filtration process becomes slow. This slow rate of filtration of kidneys results in the accumulation of uric acid in the blood. The high concentration of uric acid in the bloodstream increases the chances of having gout. Therefore, the worldwide growth rate of geriatric population is anticipated to augment the growth of the global gout therapeutics market over the forecast period.
Higher Alcohol Consumption
High consumption of alcohol have the ability to increase the chance of developing gout and it also has the potential to worsen the pre-existing gout. Alcohol consumption, especially beer, is directly related to gout as the increase in alcohol consumption is expected to cause gout because of the high purine content of alcohol. The brewer’s yeast, which is present in beer is also believed to worsen gout. For these reasons, the high alcohol consumption amongst people around the globe is anticipated to boost the growth of the global gout therapeutics market. Apart from that, rising rate of smoking among the population is also estimated to augment the growth of the market over the forecast period.
Restraints
Low Awareness
The less awareness about gout therapeutics and its advantages over the conventional methods among the middle and low income countries around the globe is anticipated to hamper the growth of the market over the forecast period.
Market Segmentation
Our-in depth analysis of the global gout therapeutics market includes the following segments:
By Drug Class
- Corticosteroids
- Colchicine
- Urate-Lowering Agents
- NSAIDs
By Disease
- Chronic Gout
- Acute Gout
By Region
On the basis of regional analysis, the global gout therapeutics market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
North America is anticipated to have the maximum share in the overall market on account of increasing adoption of gout therapy, rising investment in the healthcare sector, presence of different prominent players and increasing prevalence of gout across the region.
The Asia Pacific market is also expected to witness a significant growth which can be attributed to larger patient pool, advancement in the healthcare sector and higher investment by the countries including Japan, India and Malaysia which is further expected to drive the growth of the market.
The global gout therapeutics market is further classified on the basis of region as follows:
- North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
- Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis
Top Featured Companies Dominating The Market
- GlaxoSmithKline plc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Savient Pharmaceuticals
- AstraZeneca plc
- Merck & Co. Inc.
- Regeneron Pharmaceuticals
- Teijin Pharma Ltd.
- Takeda Pharmaceutical Company Limited
- Celgene
- Alder Biopharmaceuticals
- Other Prominent Players
